ArticleEcho research and practice2023
British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis.
Article in Echo research and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Disease-Modifying Therapies for Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis.Arquivos brasileiros de cardiologia · 2025Pooled it
- QuantitativeEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Artificial intelligence in echocardiography: a position statement from the British Society of Echocardiography.Echo research and practice · 2026Review
- Elevated filling pressures but rare restrictive physiology in transthyretin amyloid cardiomyopathy: genotype-specific patterns and the role of left atrial strain.The international journal of cardiovascular imaging · 2026Article
- Complete Heart Block Unmasking Transthyretin Cardiac Amyloidosis: A Multimodality Imaging Case Report.Cureus · 2026Article
- Pathways for Patients with Transthyretin Amyloid Cardiomyopathy from a District General Hospital Perspective.Journal of cardiovascular development and disease · 2026Article
- Position Statement on Multimodal Cardiac Imaging in Patients with Systemic Diseases - 2026.Arquivos brasileiros de cardiologia · 2026Article
- The Assessment of Interatrial Septum Thickness by Echocardiography in Wild-type Transthyretin Amyloidosis.Internal medicine (Tokyo, Japan) · 2026Article
- Development and Internal validation of a simple echocardiography score for diagnosis of cardiac amyloidosis.Journal of thoracic disease · 2026Article
- Basal inferoseptal longitudinal strain deformation may indicate early cardiac involvement in wild-type carpal ATTR.ESC heart failure · 2026Article
- Sex Differences in Hospitalizations in the 6 Months Before a Diagnosis of Transthyretin Amyloid Cardiomyopathy.JACC. Advances · 2026Article
- Bridging the Gap in AL and ATTR Cardiac Amyloidosis: Integrating Histopathology, Biomarkers, and Multimodal Imaging for Subtype-Specific Diagnosis.Reviews in cardiovascular medicine · 2026Review
- Integrating ECG and echocardiography to identify early-stage transthyretin amyloid cardiomyopathy.European heart journal. Imaging methods and practice · 2026Article
- Quantitative imaging in cardiac transthyretin amyloidosis: rationale and design of the i-CARE study.Cardiology journal · 2026Article
- Sodium-glucose cotransporter 2 inhibitors for wild-type transthyretin amyloidosis: Insights from a global database.American heart journal plus : cardiology research and practice · 2025Article
- Transplanting the unexpected: a case report of a heart allograft with wild-type transthyretin cardiac amyloid.European heart journal. Case reports · 2025Article
- Advances and challenges in echocardiographic diagnosis and management of cardiac amyloidosis.The international journal of cardiovascular imaging · 2025Review
- A Tale of Two Diseases: Decoding Aortic Stenosis and Cardiac Amyloidosis.Journal of clinical medicine · 2025Review
- Echocardiography reporting in heart failure with preserved ejection fraction: Delphi consensus study.Open heart · 2025Article
- Echocardiography and Heart Failure: An Echocardiographic Decision Aid for the Diagnosis and Management of Cardiomyopathies.Current cardiology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
These guidelines form an update of the BSE guideline protocol for the assessment of restrictive cardiomyopathy (Knight et al. in Echo Res Prac, 2013). Since the original recommendations were conceived in 2013, there has been an exponential rise in the diagnosis of cardiac amyloidosis fuelled by increased clinician awareness, improvements in cardiovascular imaging as well as the availability of new and effective disease modifying therapies. The initial diagnosis of cardiac amyloidosis can be challenging and is often not clear-cut on the basis of echocardiography, which for most patients presenting with heart failure symptoms remains the first-line imaging test. The role of a specialist echocardiographer will be to raise the suspicion of cardiac amyloidosis when appropriate, but the formal diagnosis of amyloid sub-type invariably requires further downstream testing. This document seeks to provide a focused review of the literature on echocardiography in cardiac amyloidosis highlighting its important role in the diagnosis, prognosis and screening of at risk individuals, before concluding with a suggested minimum data set, for use as an aide memoire when reporting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.